ELV.US Weekly Report · 2026-W40
Elevance Health declined 2.44% this week, closing at $386.43. The company released its 2027 Medicare Advantage plan, but the Centers for Medicare & Medicaid Services simultaneously announced a 16%+ premium reduction, creating near-term sector headwinds. Latest quarterly EPS fell 13% year-over-year; capital flows show outflows from both institutional and retail investors. While valuation sits at historically low levels, market sentiment remains volatile. Focus ahead: policy implementation details and cost management capability.
Trading Performance
Week closing price: $386.43, down 2.44% from September 25 close ($396.09). Weekly high $388.04, low $375.74, amplitude 3.21%. Weekly volume 8.93M shares; turnover rate 0.41%, consistent with 60-day median.
Daily pattern shows weakness at week-start (September 28 open), followed by continuous decline. October 1 touched the weekly low of $375.74 (−4.8% vs. week-open), indicating concentrated selling pressure. End-of-week (October 2) recovered to $386.43 on contracted volume, suggesting seller dominance persists—the relief rally lacked conviction.
Valuation Positioning
Current P/E stands at 16.89x, P/B at 1.87x. PE ranks in the 22.88th percentile of the three-year range, materially below the industry median of 23.21x. Valuation cushion is relatively ample.
Earnings Realization
Q2 2026 EPS $6.71, down 13.08% YoY; revenue $50.47B, up only 1.4% YoY; net profit $1.463B, down 16.06% YoY. Quarterly ROE fell to 13.18%. Consensus EPS forecast (Sept 18) stands at $27.1 mean, $27.01 median. Against TTM EPS of $22.88 and FY guidance floor of $20.10, near-term single-quarter earnings weakness creates tension with annual targets; H2 cost control execution becomes critical.
Capital Flows
As of October 2, institutional net inflows; but mid-tier and retail investors show outflows. Mid-tier: $408.46M in, $495.72M out, net −$87.26M; retail: $738.15M in, $925.57M out, net −$187.42M. Institutional sentiment diverges; retail sentiment turns cautious.
Institutional Consensus
Current rating distribution (as of Sept 25): 12 Strong Buy, 8 Hold, 2 Reduce; 22 total analysts. Consensus price target $451.38, implying 16.8% upside. However, ratings are inherently lagging; they fail to capture this week’s policy shock.
This Week’s News
The newsflow pivots on policy expectations. October 1, CMS announced 2027 Medicare Advantage premiums will decline 16%+—a material cost headwind for a medical insurance-driven business like Elevance. Concurrently, the company disclosed its 2027 MA plan, but market focus is on cost absorption capacity rather than revenue upside. The company also announced Q3 dividend on October 1, insufficient to support the stock price.
Key stories:
- Market Dynamics: UnitedHealth and Anthem Decline Following 2027 Plan Announcements
- Elevance Health Announces 2027 Medicare Advantage Plan
- Elevance Health (ELV) Back in Focus—What’s Driving Market Attention?
- CMS Projects 2027 Medicare Advantage Premium Cuts Exceeding 16%
- Elevance Health Declares Q3 2026 Dividend of $1.21, Payable October 1
Summary
Multi-dimensional signal divergence. Low valuation (PE 22.88th percentile) should provide support, yet price could not stabilize—reflecting market anxiety over policy impact exceeding valuation safety margin. Capital outflows clash with bullish ratings, signaling the latest policy disclosure has materially reset institutional expectations. Trailing targets lose credibility. Near-term focus: policy execution details (cost-sharing mechanisms, settlement rules) until company details a response or Q3 outlook guidance.